ＭＺＴ（株）ゼブラフィッシュ創薬研究所

Next Generation Zebrafish-based Drug Discovery

Here, we propose the strategy of zebrafish-based quantitative and systems pharmacology, which synergistically combine the desirable features of systemspharmacology and emerging technology of zebrafish-based phenotype screening system for functional omics and chemical biology.
The unique attributes of zebrafish are being increasingly leveraged to create functional disease models, facilitate drug discovery, and provide critical scientific bases for the development of new clinical tools for the diagnosis and treatment of human disease.
Zebrafish-based systems pharmacology that analyze in vivo regulatory networks involved in drug action can account for a drug's multiple targets and for the effects of genomic, epigenomic, and posttranslational changes on the drug efficacy.
The next generation discipline of systems pharmacology aims to combine experimental analysis and computational modeling of in vivo networks with quantitative pharmacology approaches to drive the drug discovery processes, predict rare adverse events, and catalyze the practice of personalized medicine.
This new systems pharmacology can drive zebrafish-based drug discovery and shape personalized medicine.

ＭＺＴ（株）ゼブラフィッシュ創薬研究所

最近の記事

Next Generation Zebrafish-based Drug Discovery

関連リンク